https://www.pharmaceutical-technology.com/news/mei-kyowa-kirin-zandelisib/
MEI Pharma and Kyowa Kirin have plans to discontinue the international development of zandelisib for B-cell malignancies outside of Japan.
kyowa kirinmeidiscontinuedevelopingzandelisib